Michel Obéid

13.9k total citations · 4 hit papers
41 papers, 7.4k citations indexed

About

Michel Obéid is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michel Obéid has authored 41 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 16 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michel Obéid's work include Cancer Immunotherapy and Biomarkers (25 papers), Phagocytosis and Immune Regulation (8 papers) and CAR-T cell therapy research (6 papers). Michel Obéid is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), Phagocytosis and Immune Regulation (8 papers) and CAR-T cell therapy research (6 papers). Michel Obéid collaborates with scholars based in Switzerland, France and United States. Michel Obéid's co-authors include Guido Kroemer, Laurence Zitvogel, François Ghiringhelli, Antoine Tesnière, Noëlia Casares, Didier Métivier, Solange Peters, Lionel Apétoh, Theocharis Panaretakis and Peter Van Endert and has published in prestigious journals such as Nature Medicine, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Michel Obéid

40 papers receiving 7.3k citations

Hit Papers

Calreticulin exposure dictates the immunogenicity of canc... 2005 2026 2012 2019 2006 2019 2005 2022 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Calreticulin exposure dictates the immunogenicity of cancer cell death
    2006 2.5k citations Michel Obéid, Antoine Tesnière et al. profile →
  2. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
    2019 1.5k citations Filipe Martins, Sofiya Latifyan et al. Nature Reviews Clinical Oncology profile →
  3. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
    2005 1.2k citations Antoine Tesnière, François Ghiringhelli et al. profile →
  4. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 565 citations John B.A.G. Haanen, Michel Obéid et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michel Obéid Switzerland 22 4.2k 3.5k 1.5k 1.1k 888 41 7.4k
Radek Špíšek Czechia 45 3.3k 0.8× 4.8k 1.4× 1.9k 1.2× 764 0.7× 829 0.9× 134 7.6k
Aitziber Buqué United States 25 3.3k 0.8× 3.2k 0.9× 1.7k 1.1× 978 0.9× 1.1k 1.2× 51 6.2k
Veena Kapoor United States 44 5.2k 1.3× 6.1k 1.7× 2.5k 1.6× 777 0.7× 1.0k 1.2× 96 10.4k
Antoine Tesnière France 20 3.2k 0.8× 4.7k 1.4× 2.1k 1.4× 651 0.6× 1.1k 1.3× 27 7.6k
Martijn P. Lolkema Netherlands 44 4.0k 1.0× 1.8k 0.5× 2.9k 1.9× 1.8k 1.6× 463 0.5× 188 8.2k
Jing Sun China 41 3.8k 0.9× 5.0k 1.4× 2.1k 1.4× 601 0.5× 612 0.7× 120 8.1k
Nathalie Chaput France 45 5.7k 1.4× 5.6k 1.6× 4.5k 2.9× 1.6k 1.4× 737 0.8× 144 11.7k
Philipp Beckhove Germany 45 4.8k 1.2× 5.0k 1.4× 1.8k 1.2× 709 0.6× 371 0.4× 150 8.4k
Eyad Elkord United Kingdom 41 4.3k 1.0× 3.9k 1.1× 2.2k 1.5× 1.1k 1.0× 443 0.5× 126 7.7k
Ferdy J. Lejeune Switzerland 44 3.3k 0.8× 3.2k 0.9× 2.6k 1.7× 1.0k 0.9× 435 0.5× 119 7.3k

Countries citing papers authored by Michel Obéid

Since Specialization
Citations

This map shows the geographic impact of Michel Obéid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Obéid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Obéid more than expected).

Fields of papers citing papers by Michel Obéid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michel Obéid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Obéid. The network helps show where Michel Obéid may publish in the future.

Co-authorship network of co-authors of Michel Obéid

This figure shows the co-authorship network connecting the top 25 collaborators of Michel Obéid. A scholar is included among the top collaborators of Michel Obéid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michel Obéid. Michel Obéid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bartolini, Robin, Lionel Trueb, Douglas Daoudlarian, et al.. (2025). Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma. Annals of Oncology. 36(7). 749–761. 1 indexed citations
2.
Obéid, Michel, Thomas Bütler, Michelle E. Armstrong, et al.. (2024). Fibroblast activation in sarcoidosis as assessed by 68Ga-FAPI (fibroblast activation protein inhibitor)-46 PET/CT. QJM. 117(8). 603–604. 1 indexed citations
3.
Sandoval, José Luís, et al.. (2023). Neoadjuvant Immunotherapy: A Promising New Standard of Care. International Journal of Molecular Sciences. 24(14). 11849–11849. 17 indexed citations
4.
Borgeaud, Maxime, José Luís Sandoval, Michel Obéid, et al.. (2023). Novel targets for immune-checkpoint inhibition in cancer. Cancer Treatment Reviews. 120. 102614–102614. 76 indexed citations
5.
Liu, Cynthia, Malek Shatila, Hao Chi Zhang, et al.. (2023). Role of C-Reactive Protein in Predicting the Severity and Response of Immune-Mediated Diarrhea and Colitis in Patients with Cancer. Journal of Cancer. 14(10). 1913–1919. 3 indexed citations
6.
Boughdad, Sarah, Sofiya Latifyan, Craig Fenwick, et al.. (2021). 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. Journal for ImmunoTherapy of Cancer. 9(10). e003594–e003594. 49 indexed citations
7.
Obéid, Michel, Craig Fenwick, & Giuseppe Pantaleo. (2021). Reactivation of IgA vasculitis after COVID-19 vaccination. The Lancet Rheumatology. 3(9). e617–e617. 53 indexed citations
8.
Haanen, John B.A.G., Marc S. Ernstoff, Yinghong Wang, et al.. (2020). Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Annals of Oncology. 31(6). 724–744. 153 indexed citations
9.
Martins, Filipe & Michel Obéid. (2020). Personalized treatment of immune-related adverse events — balance is required. Nature Reviews Clinical Oncology. 17(8). 517–517. 7 indexed citations
10.
Martins, Filipe, Sofiya Latifyan, Gerasimos P. Sykiotis, et al.. (2019). Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology. 16(9). 563–580. 1544 indexed citations breakdown →
11.
Martins, Filipe, Gerasimos P. Sykiotis, Michel H. Maillard, et al.. (2019). New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. The Lancet Oncology. 20(1). e54–e64. 141 indexed citations
12.
Horisberger, Alice, Stefano La Rosa, Stefan Zimmermann, et al.. (2018). A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. Journal for ImmunoTherapy of Cancer. 6(1). 156–156. 59 indexed citations
13.
Martins, Filipe, G. Stalder, & Michel Obéid. (2017). Generating the Abscopal Effect by Combining Proapoptotic Peptides With IL-12-Based Immunotherapy. Neoplasia. 20(2). 193–196. 3 indexed citations
14.
Obéid, Michel, Jean‐François Franetich, Audrey Lorthiois, et al.. (2012). Skin‐draining lymph node priming is sufficient to induce sterile immunity against pre‐erythrocytic malaria. EMBO Molecular Medicine. 5(2). 250–263. 30 indexed citations
15.
16.
Obéid, Michel. (2008). ERP57 Membrane Translocation Dictates the Immunogenicity of Tumor Cell Death by Controlling the Membrane Translocation of Calreticulin. The Journal of Immunology. 181(4). 2533–2543. 84 indexed citations
17.
Apétoh, Lionel, Michel Obéid, Antoine Tesnière, et al.. (2007). Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells.. PubMed. 4(2). 65–70. 22 indexed citations
18.
Chaput, Nathalie, Stéphane de Botton, Michel Obéid, et al.. (2007). Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. Journal of Molecular Medicine. 85(10). 1069–1076. 69 indexed citations
19.
Obéid, Michel, Antoine Tesnière, Theocharis Panaretakis, et al.. (2007). Ecto‐calreticulin in immunogenic chemotherapy. Immunological Reviews. 220(1). 22–34. 180 indexed citations
20.
Obéid, Michel, Theocharis Panaretakis, Antoine Tesnière, et al.. (2007). Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from “Silent” to Immunogenic. Cancer Research. 67(17). 7941–7944. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Radek Špíšek Breakdown of academic impact, for papers by Aitziber Buqué Breakdown of academic impact, for papers by Veena Kapoor Breakdown of academic impact, for papers by Antoine Tesnière Breakdown of academic impact, for papers by Martijn P. Lolkema Breakdown of academic impact, for papers by Jing Sun Breakdown of academic impact, for papers by Nathalie Chaput Breakdown of academic impact, for papers by Philipp Beckhove Breakdown of academic impact, for papers by Eyad Elkord Breakdown of academic impact, for papers by Ferdy J. Lejeune
Rankless by CCL
2026